| Trial ID: | L0651 |
| Source ID: | NCT02581124
|
| Associated Drug: |
Jtz-951
|
| Title: |
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Anemia of Chronic Kidney Disease
|
| Interventions: |
DRUG: JTZ-951|DRUG: Lapatinib
|
| Outcome Measures: |
Primary: Cmax (maximum concentration), 10 days|tmax (time to reach maximum concentration), 10 days|AUC (area under the concentration-time curve), 10 days|t1/2 (elimination half-life), 10 days|Number of adverse events, 10 days |
|
| Sponsor/Collaborators: |
Sponsor: Akros Pharma Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
10
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2015-10
|
| Completion Date: |
2016-04
|
| Results First Posted: |
|
| Last Update Posted: |
2016-04-28
|
| Locations: |
Minneapolis, Minnesota, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02581124
|
